Myriad Genetics, Inc. (FRA:MYD)

Myriad Genetics Statistics

Total Valuation

Myriad Genetics has a market cap or net worth of EUR 613.36 million. The enterprise value is 671.05 million.

Market Cap	613.36M
Enterprise Value	671.05M

Important Dates

The next estimated earnings date is Tuesday, February 24, 2026.

Earnings Date	Feb 24, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	93.21M
Shares Outstanding	n/a
Shares Change (YoY)	+2.77%
Shares Change (QoQ)	+0.65%
Owned by Insiders (%)	2.64%
Owned by Institutions (%)	92.78%
Float	85.97M

Valuation Ratios

PE Ratio	n/a
Forward PE	288.82
PS Ratio	0.87
PB Ratio	1.93
P/TBV Ratio	4.55
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-1.97
EV / Sales	0.94
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-47.15

Financial Position

The company has a current ratio of 2.33, with a Debt / Equity ratio of 0.57.

Current Ratio	2.33
Quick Ratio	1.78
Debt / Equity	0.57
Debt / EBITDA	n/a
Debt / FCF	-12.71
Interest Coverage	-12.07

Financial Efficiency

Return on equity (ROE) is -72.52% and return on invested capital (ROIC) is -7.03%.

Return on Equity (ROE)	-72.52%
Return on Assets (ROA)	-5.67%
Return on Invested Capital (ROIC)	-7.03%
Return on Capital Employed (ROCE)	-14.15%
Revenue Per Employee	260,520
Profits Per Employee	-126,425
Employee Count	2,700
Asset Turnover	0.91
Inventory Turnover	8.46

Taxes

Income Tax	-21.14M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -57.24% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-57.24%
50-Day Moving Average	6.35
200-Day Moving Average	6.06
Relative Strength Index (RSI)	56.47
Average Volume (20 Days)	17

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	6.00

Income Statement

In the last 12 months, Myriad Genetics had revenue of EUR 703.40 million and -341.35 million in losses. Loss per share was -3.72.

Revenue	703.40M
Gross Profit	494.93M
Operating Income	-69.97M
Pretax Income	-362.48M
Net Income	-341.35M
EBITDA	-22.33M
EBIT	-69.97M
Loss Per Share	-3.72

Balance Sheet

The company has 123.92 million in cash and 180.94 million in debt, giving a net cash position of -57.02 million.

Cash & Cash Equivalents	123.92M
Total Debt	180.94M
Net Cash	-57.02M
Net Cash Per Share	n/a
Equity (Book Value)	317.74M
Book Value Per Share	3.41
Working Capital	167.73M

Cash Flow

In the last 12 months, operating cash flow was -1.88 million and capital expenditures -12.36 million, giving a free cash flow of -14.23 million.

Operating Cash Flow	-1.88M
Capital Expenditures	-12.36M
Free Cash Flow	-14.23M
FCF Per Share	n/a

Margins

Gross margin is 70.36%, with operating and profit margins of -9.95% and -48.53%.

Gross Margin	70.36%
Operating Margin	-9.95%
Pretax Margin	-51.53%
Profit Margin	-48.53%
EBITDA Margin	-3.17%
EBIT Margin	-9.95%
FCF Margin	n/a

Dividends & Yields

Myriad Genetics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.77%
Shareholder Yield	-2.77%
Earnings Yield	-55.65%
FCF Yield	-2.32%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on March 26, 2009. It was a forward split with a ratio of 2.

Last Split Date	Mar 26, 2009
Split Type	Forward
Split Ratio	2

Scores

Myriad Genetics has an Altman Z-Score of 0.58 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.58
Piotroski F-Score	4